{"created":"2023-07-27T06:55:00.229828+00:00","id":50620,"links":{},"metadata":{"_buckets":{"deposit":"3b83805c-d2c6-4fda-b07b-2c8099b12b13"},"_deposit":{"created_by":18,"id":"50620","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"50620"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00050620","sets":["2812:2813:2822"]},"author_link":["2077","91645"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-04-25","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2009-2011","bibliographic_titles":[{"bibliographic_title":"平成23(2011)年度 科学研究費補助金 基盤研究(B) 研究成果報告書"},{"bibliographic_title":"2011 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"本研究では薬剤抵抗性を示す癌細胞にはテロメラーゼ依存性腫瘍溶解ウイルスが有効であることを示した。特に、表面抗原CD117/CD44陽性細胞は高い増殖能を示しプラチナ抵抗性である。この分画の細胞集団にテロメラーゼ依存性腫瘍溶解ウイルスの効果をin vitroで検討した。シスプラチン抵抗性癌細胞やヌードマウス腹膜播種モデルでも同様に抗腫瘍効果が観られた。これは融解ウイルスが薬剤抵抗性の難治性癌に有効であることを示唆する。\n次に、GFP発現型テロメラーゼ依存性腫瘍溶解ウイルス(OBP-401)によってGFP発光させ、肉眼的に可視した数個の末梢血液中の腫瘍細胞(CTC : Circulating Tumor Cell)を回収できた。Whole Genome Amplification法にてゲノム増幅後、HPV consensus primerにてPCR・制限酵素反応を行なったところ、原発巣とCTCにおいて同一のHPV-genomeが検出された。本法は様々な腫瘍での応用が可能であり、生検不能な深部病変の診断、治療法決定や癌の早期診断、非侵襲性のがん検診等に有用であると考えられる。","subitem_description_type":"Abstract"},{"subitem_description":"Despite tremendous development in chemotherapy for refractory gynecologic cancers over the past few decades, the prognosis of the advanced cases is still unsatisfactory, and novel treatment modalities are urgent needed. We developed virotherapy for solid tumors using telomerase-specific replication-selective adenoviruses(OBP-301), in which the human telomerase reverse transcriptase(hTERT) gene promoter has been inserted to direct tumor-specific E1 gene expression. In vitro treatment of Ovarian cancer cell with OBP-301 induced significant cell death in dose-dependent manner, although normal cells showed no significant cell death. Xenograft mouse model of ovarian cancer cells showed the improved survival of mice treated with Telomelysin. These findings support the therapeutic potential of virotherapy using oncolytic virus.\nOBP401 in which GFP gene is driven by the CMV-promotor, selectively replicates only in telomerase-positive cells, and therefore may be a tool for cancer screening. We collected a single cell with GFP from blood samples of cervical cancer patients and detected the same HPV-genotype in both CTC and original cancer tissues. This finding suggests that CTC detecting by OBP401 is the useful non-invasive diagnostic way for cancer screening and early detection of recurrent malignant tumors.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:21390450, 研究期間(年度):2009-2011","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「難治性婦人科がんに対する腫瘍融解ウイルス治療法の開発」課題番号21390450\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-21390450/21390450seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00056929","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_17":{"attribute_name":"公開者","attribute_value_mlt":[{"subitem_publisher":"金沢大学医薬保健研究域医学系"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=10127186"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=10127186","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390450/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390450/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-21390450/21390450seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-21390450/21390450seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-10"}],"displaytype":"detail","filename":"ME-PR-INOUE-M-kaken 2012-4p.pdf","filesize":[{"value":"216.1 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-INOUE-M-kaken 2012-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/50620/files/ME-PR-INOUE-M-kaken 2012-4p.pdf"},"version_id":"e00ffa75-ec1a-45b6-95d8-526857cc7026"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"難治性婦人科がんに対する腫瘍融解ウイルス治療法の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"難治性婦人科がんに対する腫瘍融解ウイルス治療法の開発"},{"subitem_title":"Development of oncolytic virotherapy against the refractory gynecologic cancers","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2822"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-02-10"},"publish_date":"2020-02-10","publish_status":"0","recid":"50620","relation_version_is_last":true,"title":["難治性婦人科がんに対する腫瘍融解ウイルス治療法の開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T13:24:53.521667+00:00"}